Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions.
Vogelzang
N J
NJ
Lestingi
T M
TM
Sudakoff
G
G
Kradjian
S A
SA
D000328:Adult; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D002985:Clinical Protocols; D004274:DNA, Recombinant / Q000008:administration & dosage*; D005260:Female; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D015793:HLA-B7 Antigen / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D007258:Informed Consent; D015552:Injections, Intralesional; D007680:Kidney Neoplasms; D008055:Lipids / Q000008:administration & dosage; D008297:Male; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000276:immunology / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D004274:DNA, Recombinant; D015793:HLA-B7 Antigen; D008055:Lipids; D011993:Recombinant Fusion Proteins